Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Chronic lymphocytic leukemia is characterized by relapse after treatment and chemotherapy resistance. Similarly, in other malignancies leukemia cells accumulate mutations during growth, forming heterogeneous cell populations that are subject to Darwinian selection and may respond differentially to treatment. There is therefore a clinical need to monitor changes in the subclonal composition of cancers during disease progression. Here, we use whole-genome sequencing to track subclonal heterogeneity in 3 chronic lymphocytic leukemia patients subjected to repeated cycles of therapy. We reveal different somatic mutation profiles in each patient and use these to establish probable hierarchical patterns of subclonal evolution, to identify subclones that decline or expand over time, and to detect founder mutations. We show that clonal evolution patterns are heterogeneous in individual patients. We conclude that genome sequencing is a powerful and sensitive approach to monitor disease progression repeatedly at the molecular level. If applied to future clinical trials, this approach might eventually influence treatment strategies as a tool to individualize and direct cancer treatment.

Original publication

DOI

10.1182/blood-2012-05-433540

Type

Journal article

Journal

Blood

Publication Date

15/11/2012

Volume

120

Pages

4191 - 4196

Keywords

Alleles, Cell Transformation, Neoplastic, Clonal Deletion, Clone Cells, DNA Mutational Analysis, DNA, Neoplasm, Disease Progression, Evolution, Molecular, Gene Frequency, Genome-Wide Association Study, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Mutation, Neoplasm Proteins, Selection, Genetic, Sequence Analysis, DNA